UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.033

Sortiert nach

The Immunoscore: Colon Cancer and Beyond

Clinical cancer research, 2020-01, Vol.26 (2), p.332-339

2020

Volltextzugriff (PDF)

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Nucleic acids research, 2016-06, Vol.44 (11), p.e108

2016

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.509-515

2015

Volltextzugriff (PDF)

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Volltextzugriff (PDF)

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

Nature reviews. Drug discovery, 2018-03, Vol.17 (3), p.167-181

2018

Volltextzugriff (PDF)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Nature communications, 2021-03, Vol.12 (1), p.1780-1780, Article 1780

2021

Volltextzugriff (PDF)

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Clinical cancer research, 2017-08, Vol.23 (15), p.4086-4094

2017

Volltextzugriff (PDF)

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13), p.2587-2593

2015

Volltextzugriff (PDF)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

British journal of cancer, 2018-11, Vol.119 (11), p.1401-1409

2018

Volltextzugriff (PDF)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Volltextzugriff (PDF)

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Nature (London), 2021-09, Vol.597 (7877), p.527-532

2021

Volltextzugriff (PDF)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

British journal of cancer, 2021-12, Vol.125 (12), p.1666-1676

2021

Volltextzugriff (PDF)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Scientific reports, 2022-02, Vol.12 (1), p.2699-2699, Article 2699

2022

Volltextzugriff (PDF)

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Clinical cancer research, 2020-05, Vol.26 (9), p.2176-2187

2020

Volltextzugriff (PDF)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Nature communications, 2023-02, Vol.14 (1), p.1071-1071, Article 1071

2023

Volltextzugriff (PDF)

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group

Clinical chemistry (Baltimore, Md.), 2020-09, Vol.66 (9), p.1156-1166

2020

Volltextzugriff (PDF)

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins

Molecular biology of the cell, 2005-10, Vol.16 (10), p.4623-4635

2005

Volltextzugriff (PDF)

Defining actionable mutations for oncology therapeutic development

Nature reviews. Cancer, 2016-05, Vol.16 (5), p.319

2016

Volltextzugriff (PDF)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Cancers, 2021-11, Vol.13 (22), p.5830

2021

Volltextzugriff (PDF)

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Clinical cancer research, 2018-12, Vol.24 (23), p.5860-5872

2018

Volltextzugriff (PDF)

1 – 25 von 1.033

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(963)
Mit Volltextzugriff
(953)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.030)
Japanisch
(167)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(646)
Life Sciences & Biomedicine
(576)
Humans
(476)
Animals
(307)
Oncology
(275)
Biological And Medical Sciences
(264)
Female
(209)
Medical Sciences
(191)
Tumors
(165)
Male
(142)
Mice
(138)
Mutation
(98)
Biochemistry & Molecular Biology
(95)
Cricetinae
(90)
Tumor Cells, Cultured
(90)
Fundamental And Applied Biological Sciences. Psychology
(88)
Adult
(84)
Cells, Cultured
(74)
Genetics & Heredity
(73)
Cell Line
(68)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

The Immunoscore: Colon Cancer and Beyond

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins

Defining actionable mutations for oncology therapeutic development

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Suchergebnisse filtern